In a letter to the Department of Commerce, Novo Nordisk argued that unsanctioned compounded semaglutide, mostly from China, ...

Novo Nordisk boosts Wegovy access with discounts as FDA bans compounded semaglutide drugs and cracks down on weight-loss ...

senior vice president and head of Chief Medical Office at Novo Nordisk. “Our broad and robust semaglutide data presented at ECO, including its impact on weight loss in a real-world setting and ...

Novo Nordisk A/S announced its Q1 earnings today, blaming a slight revenue miss on sales of compounded semaglutide. Q1 2025 earnings showed revenue of ~$11.9bn, operating profit of $5.9bn ...

Facing steep competition, Novo Nordisk has slashed the price for its weight loss drug Wegovy — temporarily, at least.

Without effective interventions, the global burden of obesity and its complications will continue to rise,” said Stephen Gough, senior vice president and head of Chief Medical Office at Novo Nordisk. ...

Ozempic-maker Novo Nordisk on Friday ousted its CEO Lars Fruergaard Jorgensen over concerns the company is losing its first-mover advantage in the competitive obesity drug market to American rival Eli ...

One of the biggest risks Novo Nordisk faced was that companies like Hims & Hers could exploit a legal loophole to sell compounded semaglutide. A few weeks ago, however, a piece of news changed the ...

Novo Nordisk (NVO) is offering a one-month reduction in the price of its blockbuster weight-loss GLP-1 drug to help encourage ...

Novo Nordisk abstracts to be presented, some of these data for semaglutide are investigational: Predicting weight loss using self-reported, digitally collected, real-world data after initiation of ...